OBJECTIVES: Therapeutic hypothermia is widely employed for neuroprotection after cardiac arrest. However, concern regarding elevated drug concentrations during hypothermia and increased adverse drug reaction risk complicates concurrent pharmacotherapy. Many commonly used medications in critically ill patients rely on the cytochrome P450 3A isoform for their elimination. Therefore, our study objectives were to determine the effect of mild hypothermia on the in vivo pharmacokinetics of fentanyl and midazolam, two clinically relevant cytochrome P450 3A substrates, after cardiac arrest and to investigate the mechanisms of these alterations. DESIGN: Prospective, randomized, controlled study. SETTING: University research laboratory. SUBJECTS: Thirty-two adult male Sprague-Dawley rats. INTERVENTIONS: An asphyxial cardiac arrest rat model was used and mild hypothermia (33°C) was induced 1 hr post injury by surface cooling and continued for 10 hrs to mimic the prolonged clinical application of hypothermia accompanied by intensive care interventions. Fentanyl and midazolam were independently administered by intravenous infusion and plasma and brain concentrations were analyzed using ultraperformance liquid chromatography tandem mass spectrometry. Cytochrome P450 3a2 protein expression was measured and a Michaelis-Menten enzyme kinetic analysis was performed at 37°C and 33°C using control rat microsomes. MEASUREMENTS AND MAIN RESULTS: Mild hypothermia decreased the systemic clearance of both fentanyl (61.5 ± 11.5 to 48.9 ± 8.95 mL/min/kg; p < .05) and midazolam (89.2 ± 12.5 to 73.6 ± 12.1 mL/min/kg; p < .05) after cardiac arrest. The elevated systemic concentrations did not lead to parallel increased brain exposures of either drug. Mechanistically, no differences in cytochrome P450 3a2 expression was observed, but the in vitro metabolism of both drugs was decreased at 33°C vs. 37°C through reductions in enzyme metabolic capacity rather than substrate affinity. CONCLUSIONS: Mild hypothermia reduces the systemic clearances of fentanyl and midazolam in rats after cardiac arrest through alterations in cytochrome P450 3a2 metabolic capacity rather than enzyme affinity as observed with other cytochrome P450s. Contrasting effects on blood and brain levels further complicates drug dosing. Consideration of the impact of hypothermia on medications whose clearance is dependent on P450 3A metabolism is warranted.
OBJECTIVES: Therapeutic hypothermia is widely employed for neuroprotection after cardiac arrest. However, concern regarding elevated drug concentrations during hypothermia and increased adverse drug reaction risk complicates concurrent pharmacotherapy. Many commonly used medications in critically illpatients rely on the cytochrome P450 3A isoform for their elimination. Therefore, our study objectives were to determine the effect of mild hypothermia on the in vivo pharmacokinetics of fentanyl and midazolam, two clinically relevant cytochrome P450 3A substrates, after cardiac arrest and to investigate the mechanisms of these alterations. DESIGN: Prospective, randomized, controlled study. SETTING: University research laboratory. SUBJECTS: Thirty-two adult male Sprague-Dawley rats. INTERVENTIONS: An asphyxial cardiac arrestrat model was used and mild hypothermia (33°C) was induced 1 hr post injury by surface cooling and continued for 10 hrs to mimic the prolonged clinical application of hypothermia accompanied by intensive care interventions. Fentanyl and midazolam were independently administered by intravenous infusion and plasma and brain concentrations were analyzed using ultraperformance liquid chromatography tandem mass spectrometry. Cytochrome P450 3a2 protein expression was measured and a Michaelis-Menten enzyme kinetic analysis was performed at 37°C and 33°C using control rat microsomes. MEASUREMENTS AND MAIN RESULTS: Mild hypothermia decreased the systemic clearance of both fentanyl (61.5 ± 11.5 to 48.9 ± 8.95 mL/min/kg; p < .05) and midazolam (89.2 ± 12.5 to 73.6 ± 12.1 mL/min/kg; p < .05) after cardiac arrest. The elevated systemic concentrations did not lead to parallel increased brain exposures of either drug. Mechanistically, no differences in cytochrome P450 3a2 expression was observed, but the in vitro metabolism of both drugs was decreased at 33°C vs. 37°C through reductions in enzyme metabolic capacity rather than substrate affinity. CONCLUSIONS: Mild hypothermia reduces the systemic clearances of fentanyl and midazolam in rats after cardiac arrest through alterations in cytochrome P450 3a2 metabolic capacity rather than enzyme affinity as observed with other cytochrome P450s. Contrasting effects on blood and brain levels further complicates drug dosing. Consideration of the impact of hypothermia on medications whose clearance is dependent on P450 3A metabolism is warranted.
Authors: J E Caldwell; T Heier; P M Wright; S Lin; G McCarthy; J Szenohradszky; M L Sharma; J P Hing; M Schroeder; D I Sessler Journal: Anesthesiology Date: 2000-01 Impact factor: 7.892
Authors: Isabel Spriet; Wouter Meersseman; Jan de Hoon; Sandrina von Winckelmann; Alexander Wilmer; Ludo Willems Journal: Intensive Care Med Date: 2009-01-09 Impact factor: 17.440
Authors: N Joan Abbott; Adjanie A K Patabendige; Diana E M Dolman; Siti R Yusof; David J Begley Journal: Neurobiol Dis Date: 2009-08-05 Impact factor: 5.996
Authors: Anikó Róka; Kis Tamas Melinda; Barna Vásárhelyi; Tamás Machay; Denis Azzopardi; Miklós Szabó Journal: Pediatrics Date: 2008-04 Impact factor: 7.124
Authors: Iman A Elkiweri; Yan Ling Zhang; Uwe Christians; Ka-Yun Ng; Martha C Tissot van Patot; Thomas K Henthorn Journal: Anesth Analg Date: 2009-01 Impact factor: 5.108
Authors: David Hostler; Jiangquan Zhou; Michael A Tortorici; Robert R Bies; Jon C Rittenberger; Philip E Empey; Patrick M Kochanek; Clifton W Callaway; Samuel M Poloyac Journal: Drug Metab Dispos Date: 2010-02-17 Impact factor: 3.922
Authors: Erica Kundrick; Brenda Marrero-Rosado; Michael Stone; Caroline Schultz; Katie Walker; Robyn B Lee-Stubbs; Marcio de Araujo Furtado; Lucille A Lumley Journal: Ann N Y Acad Sci Date: 2020-02-06 Impact factor: 5.691
Authors: Fanuel T Hagos; Christopher M Horvat; Alicia K Au; Yvette P Conley; Lingjue Li; Samuel M Poloyac; Patrick M Kochanek; Robert S B Clark; Philip E Empey Journal: Clin Pharmacokinet Date: 2019-12 Impact factor: 6.447
Authors: Enno D Wildschut; Annewil van Saet; Pavla Pokorna; Maurice J Ahsman; John N Van den Anker; Dick Tibboel Journal: Pediatr Clin North Am Date: 2012-08-29 Impact factor: 3.278
Authors: Kacey B Anderson; Samuel M Poloyac; Patrick M Kochanek; Philip E Empey Journal: Ther Hypothermia Temp Manag Date: 2016-09-13 Impact factor: 1.286
Authors: Philip E Empey; Nieves Velez de Mendizabal; Michael J Bell; Robert R Bies; Kacey B Anderson; Patrick M Kochanek; P David Adelson; Samuel M Poloyac Journal: Crit Care Med Date: 2013-10 Impact factor: 7.598